The aim of this study was to identify factors predicting large post-void residual (PVR) (defined as ≥200 mL), an important unsolved problem, after an intravesical injection of onabotulinumtoxinA in patients with overactive bladder syndrome. The data showed that 133 of 290 patients had a large PVR after treatment. Multivariate analysis found that the baseline 3-day daytime frequency episodes and...

In the last few years, much new information has been generated on the pathophysiology, possible therapeutic targets, and pharmacologic treatment of overactive bladder (OAB). Antimuscarinic drugs are still first-line pharmacologic treatment for OAB and often have good initial response rates, but adverse effects and decreasing efficacy cause long-term compliance problems, prompting a search for n...

Erratum to " The Urologist's View of Male Overactive Bladder: Discrepancy between Reality and Belief in Practical Setting " by Lee SH, et al. The 2 nd author was omitted. So, we would like to correct affiliation of some of the authors as shown below. Changes are marked by underlines. The authors regret these errors.

OBJECTIVES This article aims to analyse the use of solifenacin in the treatment of overactive bladder in order to show its efficacy and safety within the framework of the scientific evidence. METHODS The available scientific literature was reviewed, including most of the relevant clinical trials performed with solifenacin. RESULTS All the studies analysed show significant improvements in pa...

INTRODUCTION Overactive bladder (OAB) is a prevalent and persistent condition that is often under-diagnosed and under-treated, and which frequently requires tailored treatment for successful management. METHODS This consensus opinion-based review summarizes the discussions of a group of experts in the field of OAB that were assembled to evaluate the importance of correct diagnosis and appropr...

Alfredo di Pino, MD, Elio Caruso, MD, Federica Censi, PhD, Gianfranco Gaudenti, EEng, Alessio Gargaro, MS, Giovanni Calcagnini, PhD From the Department of Pediatric Cardiology and Cardiac Surgery, Bambino Gesù Children’s Hospital Centro Cardiologico Pediatrico del Mediterraneo, San Vincenzo Hospital, Taormina, Italy, Department of Technology and Health, Italian National Institute of Health, Rom...

PURPOSE To discuss the pharmacotherapeutic aspects of Mirabegron which is a first-in class novel β3 receptor agonist drug recently approved by the food and drug administration (FDA) for the treatment of overactive bladder (OAB). MATERIALS AND METHODS We conducted a computerized search of the MEDLINE/PUBMED databases with the word Mirabegron, β3 receptor agonist and overactive bladder. RESUL...